Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate) Phase 3 Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting

Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate) Phase 3 Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting

New Brunswick, NJ (May 25, 2012) -- Johnson & Johnson will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time, to coincide with the American Society of Clinical Oncology’s (ASCO) Annual Meeting in Chicago, Ill.

Results from pre-specified interim analyses of COU-AA-302, a randomized, phase 3 study of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer, will be shown for the first time at ASCO.

The pre-recorded webcast with management from the Company’s Janssen pharmaceutical subsidiaries, will provide an update on the results of the COU-AA-302 study and an update on the initial launch of ZYTIGA^® (abiraterone acetate).

The webcast/podcast and replay can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.”

###

Press Contacts:
Al Wasilewski
(732) 524-1130

Bill Price
(732) 524-6623

Investor Contacts:
Stan Panasewicz
(732) 524-2524

Louise Mehrotra
(732) 524-6491